Literature DB >> 12206577

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

K Coyne1, D Revicki, T Hunt, R Corey, W Stewart, J Bentkover, H Kurth, P Abrams.   

Abstract

OBJECTIVE: Overactive bladder (OAB) is characterized by symptoms of urinary frequency and urgency, with and without incontinence, and has been shown to have significant impact on health-related quality of life (HRQL). Currently, no OAB-specific questionnaires exist to evaluate all symptoms of OAB; thus we sought to evaluate the psychometric properties of a newly developed OAB HRQL questionnaire.
METHODS: The 33-item, self-administered OAB-q contains a symptom bother and HRQL scale. Both the OAB-q and SF-36 were completed by participants from two sources: (1) a community sample who screened positive for OAB in a random-digit dial telephone survey and participated in a clinical validation study (n = 254); and (2) a clinical study of patients' seeking treatment for OAB symptoms (baseline assessment) (n = 736). Item and exploratory factor analysis were performed to assess the subscale structure of the questionnaire. Psychometric evaluation was conducted to assess reliability and validity.
RESULTS: Seventy-four percent of the sample were women with mean age of 58.5. Participants with continent and incontinent symptoms reported significantly greater symptom bother and HRQL impact than normal participants. Significant differences were present among all patient groups in all OAB-q subscales (p < 0.0001) except sleep where the impact of continent and incontinent OAB was similar, but significantly worse than normal participants (p < 0.0001). Internal consistency was high with the subscale Cronbach alpha-values ranging from 0.86 to 0.94.
CONCLUSION: The OAB-q is a reliable and valid instrument that discriminates between normal and clinically diagnosed continent and incontinent OAB participants. The OAB-q demonstrates that both continent and incontinent OAB symptoms cause significant symptom bother and have a negative impact on HRQL.

Entities:  

Mesh:

Year:  2002        PMID: 12206577     DOI: 10.1023/a:1016370925601

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  23 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Recommendations for evaluating the validity of quality of life claims for labeling and promotion.

Authors:  N K Leidy; D A Revicki; B Genesté
Journal:  Value Health       Date:  1999 Mar-Apr       Impact factor: 5.725

3.  Urinary symptoms in the community: how bothersome are they?

Authors:  J V Jolleys; J L Donovan; K Nanchahal; T J Peters; P Abrams
Journal:  Br J Urol       Date:  1994-11

4.  Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey.

Authors:  J N Liberman; T L Hunt; W F Stewart; A Wein; Z Zhou; A R Herzog; R B Lipton; A C Diokno
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

5.  Urge incontinence: new health-related quality of life measures.

Authors:  J S Brown; S F Posner; A L Stewart
Journal:  J Am Geriatr Soc       Date:  1999-08       Impact factor: 5.562

6.  The quality of life in women with urinary incontinence as measured by the sickness impact profile.

Authors:  S Hunskaar; A Vinsnes
Journal:  J Am Geriatr Soc       Date:  1991-04       Impact factor: 5.562

7.  Urge incontinence. Quality of life and patients' valuation of symptom reduction.

Authors:  R M O'Conor; M Johannesson; S L Hass; G Kobelt-Nguyen
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

8.  The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing.

Authors:  S Jackson; J Donovan; S Brookes; S Eckford; L Swithinbank; P Abrams
Journal:  Br J Urol       Date:  1996-06

9.  Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group.

Authors:  S A Shumaker; J F Wyman; J S Uebersax; D McClish; J A Fantl
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

10.  Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.

Authors:  Y Harati; C Gooch; M Swenson; S Edelman; D Greene; P Raskin; P Donofrio; D Cornblath; R Sachdeo; C O Siu; M Kamin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  144 in total

1.  Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale.

Authors:  John Brazier; Donna Rowen; Yaling Yang; Aki Tsuchiya
Journal:  Eur J Health Econ       Date:  2011-09-30

2.  Does Instruction to Eliminate Coffee, Tea, Alcohol, Carbonated, and Artificially Sweetened Beverages Improve Lower Urinary Tract Symptoms?: A Prospective Trial.

Authors:  Janis M Miller; Caroline E Garcia; Sarah Becker Hortsch; Ying Guo; Megan O Schimpf
Journal:  J Wound Ostomy Continence Nurs       Date:  2016 Jan-Feb       Impact factor: 1.741

Review 3.  Fesoterodine for overactive bladder: A review of the literature.

Authors:  Kanchan Gupta; Kirandeep Kaur; Baldev Singh Aulakh; Sandeep Kaushal
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

4.  Temporal summation to thermal stimuli is elevated in women with overactive bladder syndrome.

Authors:  William Stuart Reynolds; Elizabeth Timbrook Brown; Jill Danford; Melissa Kaufman; Alan Wein; Roger Dmochowski; Stephen Bruehl
Journal:  Neurourol Urodyn       Date:  2016-07-19       Impact factor: 2.696

5.  Overactive bladder in adults with sickle cell disease.

Authors:  Uzoma A Anele; Belinda F Morrison; Marvin E Reid; Wendy Madden; Shara Foster; Arthur L Burnett
Journal:  Neurourol Urodyn       Date:  2015-04-14       Impact factor: 2.696

6.  Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.

Authors:  Jonathan S Starkman; John W Duffy; Christopher E Wolter; Melissa R Kaufman; Harriette M Scarpero; Roger R Dmochowski
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-08-02

7.  Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Authors:  Marc R Toglia; Donald R Ostergard; Rodney A Appell; Masakazu Andoh; Allam Fakhoury; Iqbal F Hussain
Journal:  Int Urogynecol J       Date:  2010-03-26       Impact factor: 2.894

8.  Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.

Authors:  Yaoguang Zhang; Peng Zhang; Xiaojun Tian; Guoqing Chen; Yan Li; Yong Zhang; Zhihui Xu; Zhongqing Wei; Wei Zhang; Lulin Ma; Benkang Shi; Limin Liao; Jianye Wang
Journal:  World J Urol       Date:  2019-02-26       Impact factor: 4.226

Review 9.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

10.  Does concomitant anterior/apical repair during midurethral sling improve the overactive bladder component of mixed incontinence?

Authors:  Alexis A Dieter; Autumn L Edenfield; Alison C Weidner; Pamela J Levin; Nazema Y Siddiqui
Journal:  Int Urogynecol J       Date:  2014-05-09       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.